GF
TRIB

Gabelli Funds’s Trinity Biotech TRIB Stock Holding History

Gabelli Funds’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-530
Closed -$909K – 1158
2015
Q3 		$909K Hold
530
– – 0.01% 865
2015
Q2 		$1.44M Hold
530
– – 0.01% 822
2015
Q1 		$1.53M Hold
530
– – 0.01% 816
2014
Q4 		$1.39M Buy
530
+333
+169% +$861K 0.01% 840
2014
Q3 		$539K Buy
+197
New +$640K ﹤0.01% 970

Other funds holding TRIB

Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $856M AUM 70.44% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Gabelli Funds's TRIB Position: Q4 2015 in Review

Gabelli Funds sold out of Trinity Biotech (TRIB) in Q4 2015, closing a stake of 530 shares — an estimated $909K sold.

Gabelli Funds first reported a position in TRIB in Q3 2014 and held it in 5 quarters. The position peaked at $1.53M in Q1 2015. 81 funds tracked by Wall St. Rank hold TRIB as of Q4 2015.

  • Gabelli Funds reported no remaining Trinity Biotech position as of Q4 2015 after selling out during the quarter.
  • Gabelli Funds sold 530 Trinity Biotech shares in Q4 2015, an estimated $909K.
  • Gabelli Funds first reported a position in Trinity Biotech in Q3 2014 and held it in 5 quarters.
  • Gabelli Funds's Trinity Biotech position peaked at $1.53M in Q1 2015.
  • 81 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2015.

Based on Gabelli Funds's 13F filing for Q4 2015, filed 5 Feb 2016.